FDA Downgrades Hepatitis B Tests to Faster Approval Category
Published Date: 9/18/2025
Rule
Summary
The FDA is changing the rules for certain hepatitis B test devices, moving them from a strict category (Class III) to a less strict one (Class II) with special safety rules. This affects companies making HBV antigen, antibody, and nucleic acid tests, who now need to follow new guidelines and submit notifications before selling. These changes help speed up access to safe, reliable hepatitis B tests without extra costs or delays.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Manufacturers Must File Premarket Notices
If you make hepatitis B test devices, the FDA moved certain tests into class II and says you must follow new special controls and submit a premarket notification before marketing. This applies to qualitative HBV antigen assays (product code LOM), HBV antibody assays (product code LOM), and quantitative HBV nucleic acid-based assays (product code MKT).
Easier Access to Hepatitis B Tests
If you need a hepatitis B test, the FDA reclassified certain HBV antigen, antibody, and nucleic acid tests to class II with special controls and now allows them to be marketed after premarket notification. This change is meant to help speed access to safe, reliable hepatitis B tests for patients because those device types are now subject to the class II pathway.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16944, Gardenia Blue Interest Group; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by Gardenia Blue Interest Group (GBIG or petitioner), c/o Exponent, Inc., proposing that we amend our color additive regulations to expand the safe use of gardenia (genipin) blue in various foods at levels consistent with good manufacturing practice. The petition also proposes to lower the specification for arsenic in gardenia (genipin) blue.
2026-16939, GNT USA, LLC.; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by GNT USA, LLC., c/o Exponent, Inc., proposing that we amend our color additive regulations to provide for the safe use of safflower (Carthamus tinctorius L.) extract as a color additive in various foods at levels consistent with good manufacturing practices.
2026-16943, International Association of Color Manufacturers; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by the International Association of Color Manufacturers, proposing that we amend our color additive regulations to provide for the safe use of acetone as a solvent in the manufacture of carrot oil. The petition also proposes to add heavy metal limits and secondary names for carrot oil. FDA may also consider other changes to the regulation, as appropriate, during the course of our review.
Previous / Next Documents
Previous: 2025-18080, Radiological Health Regulations; Technical Amendments
The FDA fixed a mistake in its radiological health rules by putting back some important text that was accidentally removed last year. This update helps keep the rules clear and accurate for companies making X-ray, laser, and ultrasound products. No new costs or deadlines—just a tidy correction to keep things running smoothly.
Next: 2025-18083, Airworthiness Directives; Airbus Helicopters
If you fly certain Airbus Helicopters like the AS350B3 or EC130 models, this new rule updates old safety checks on the throttle twist grip. It keeps the previous inspections but adds a fix that stops the need for repeated checks. Plus, it stops using certain parts that caused engines to stay stuck in idle, keeping flights safer and smoother without extra costs piling up.